Compare CMP & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMP | SLDB |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2003 | 2017 |
| Metric | CMP | SLDB |
|---|---|---|
| Price | $25.63 | $9.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $21.50 | $16.36 |
| AVG Volume (30 Days) | 374.9K | ★ 764.8K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ 0.59 | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | $43.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.40 | $3.79 |
| 52 Week High | $34.50 | $11.45 |
| Indicator | CMP | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 53.32 |
| Support Level | $24.49 | $5.21 |
| Resistance Level | $25.80 | $11.45 |
| Average True Range (ATR) | 0.89 | 0.44 |
| MACD | 0.25 | 0.01 |
| Stochastic Oscillator | 72.32 | 54.19 |
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.